Global Blood Therapeutics Stock News

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Equities research analysts at SVB Leerink boosted their FY2021 earnings per share estimates for shares of Global Blood Therapeutics in a research note issued on Monday, December 20th. SVB Leerink analyst A. Berens now anticipates that the company will earn ($4.73) per share for the year, up from their []

Global Blood Therapeutics, Inc. (NASDAQ:GBT) SVB Leerink upped their FY2021 earnings per share estimates for shares of Global Blood Therapeutics in a research note issued to investors on Monday, December 20th. SVB Leerink analyst A. Berens now expects that the company will earn ($4.73) per share for the year, up from their prior estimate []

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Wedbush lifted their FY2022 earnings estimates for Global Blood Therapeutics in a research note issued on Monday, December 20th. Wedbush analyst L. Moussatos now expects that the company will earn ($4.05) per share for the year, up from their previous forecast of ($4.07). Wedbush has a Buy rating on []

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Investment analysts at Oppenheimer cut their Q1 2022 earnings per share estimates for shares of Global Blood Therapeutics in a research note issued on Monday, December 20th. Oppenheimer analyst M. Breidenbach now expects that the company will post earnings of ($1.07) per share for the quarter, down from their [] The post Q1 2022 Earnings Forecast for Global Blood Therapeutics, Inc. (NASDAQ:GBT) Issued By Oppenheimer appeared first on ETF Daily News .

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Analysts at Oppenheimer dropped their Q1 2022 earnings estimates for Global Blood Therapeutics in a report issued on Monday, December 20th. Oppenheimer analyst M. Breidenbach now expects that the company will post earnings of ($1.07) per share for the quarter, down from their previous forecast of ($1.03). Oppenheimer also []

Global Blood Therapeutics (NASDAQ:GBT) had its target price decreased by SVB Leerink from $56.00 to $53.00 in a research note released on Tuesday morning, Analyst Price Targets reports. SVB Leerink currently has an outperform rating on the stock. Several other research firms have also recently weighed in on GBT. Royal Bank of Canada decreased their []

Global Blood Therapeutics, Inc. (NASDAQ:GBT) has been assigned an average recommendation of Buy from the fourteen brokerages that are currently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12 month price objective among brokers []

The FDA approves Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to less the 12 years, and NDA for a pediatric weight-based formulation of the drug.

The FDA has granted accelerated approval to Global Blood Therapeutics Inc''s (NASDAQ: GBT ) supplemental application seeking approval for Oxbryta (voxelotor) tablets for sickle cell disease (SCD) in children ages 4 to less than 12 years. This approval expands the previously approved use of Full story available on Benzinga.com

European Commission decision on marketing authorization anticipated first quarter of 2022 Oxbryta would be the first oral treatment available in Europe to directly inhibit sickle hemoglobin (HbS) p

European Commission decision on marketing authorization anticipated first quarter of 2022 Oxbryta would be the first oral treatment available in Europe to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell disease HbS polymerization and red blood cell sickling drive deterioration of red blood cell health and result in hemolysis and hemolytic anemia, leading to inflammation, organ damage and early death SOUTH SAN FRANCISCO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for Oxbryta ® ( voxelotor) tablets for the treatment of hemolytic anemia due to sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea). Oxbryta, an oral treatment taken once daily, would be the first medicine available in Europe that directly inhibits sickle hemoglobin (HbS) polymerization, the molecular cause of sickling and destruction of red blood cells in SCD.

Wall Street analysts forecast that Global Blood Therapeutics, Inc. (NASDAQ:GBT) will report ($1.14) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Twelve analysts have issued estimates for Global Blood Therapeutics earnings, with the lowest EPS estimate coming in at ($1.31) and the highest estimate coming in at ($0.94). Global Blood []

Global Blood Therapeutics Inc (NASDAQ: GBT) priced $300 million Convertible Senior Notes due 2028 in a private offering.  The offering size was increased from the previously announced offering siz